Keyword: Procrit

AstraZeneca

5. Roxadustat

FibroGen's AstraZeneca-partnered anemia drug roxadustat was first approved in China. Leerink analyst Geoffrey Porges has projected sales of about $1 billion in China alone by 2025.

6. Epogen/Procrit

Biosimilars to Amgen's Epogen have been available on the European market for more than a decade, but so far the U.S. biosimilars market has lagged and copycats aren't available. While uncertain due to regulatory stumbles, this might be the year the blockbuster has to face off against a cheap rival.